Derivation of Dendritic Cell-Specific Adenovirus Vectors

Information

  • Research Project
  • 6337349
  • ApplicationId
    6337349
  • Core Project Number
    R41CA091608
  • Full Project Number
    1R41CA091608-01
  • Serial Number
    91608
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/21/2001 - 24 years ago
  • Project End Date
    9/30/2002 - 23 years ago
  • Program Officer Name
    MUSZYNSKI, KAREN
  • Budget Start Date
    9/21/2001 - 24 years ago
  • Budget End Date
    9/30/2002 - 23 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/18/2001 - 24 years ago
Organizations

Derivation of Dendritic Cell-Specific Adenovirus Vectors

DESCRIPTION (provided by applicant): The long-range goal of this research project is to develop a novel and effective strategy for transduction of human dendritic cells (DC) for the purposes of genetic anti-tumor immunization. To accomplish this goal, we will develop an adenovirus(Ad)-based gene delivery system capable of efficient and specific transduction of DC by utilizing the natural mechanism of CD4OL-CD4O interaction. As a result, we will develop a novel viral vector capable of eliciting a potent immune response to a vector-encoded immunogen by efficient transduction of DC. The first specific aim is to design a recombinant protein chimera incorporating structural elements of the Ad5 fiber and CD4OL molecules, and possessing the key features of both parental proteins. The second specific aim is to show the feasibility of incorporation of the fiber-CD4OL chimeric proteins into viable Ad virions and demonstrate the ability of these viral vectors to achieve CD40-specific gene transfer. The experimental plan will include modeling of the fiber-CD4OL chimeric proteins, extensive structural and functional characterization of these proteins expressed in E.coli, incorporation of these chimeras into Ad virions and demonstration of the DC-specificity of these viral vectors. The goal of this project is to develop adenoviral vectors that can target the dendritic cells (DC) through CD-40 receptor. PROPOSED COMMERCIAL APPLICATION: Not available

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R41
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    VECTORLOGICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BIRMINGHAM
  • Organization State
    AL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    35294
  • Organization District
    UNITED STATES